NRIX

insider transactions

Nurix Therapeutics, Inc. — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

Net shares · 90d

-52.7K

0 buy · 52.7K sell

Net value · 90d

-$868.1K

$0 in · $868.1K out

Sentiment · 90d

Net selling

0% buying · 100% selling

Open-market trades · 90d

0 buy · 52.7K sell

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Exercise·M
Jun 2, 26

Christine Ring

Chief Legal Officer · 10b5-1

$0

3.4K sh

Own +190%
Sell·S
Jun 2, 26

Christine Ring

Chief Legal Officer · 10b5-1

$135.3K

8.1K sh · $16.60

Own -38%
Exercise·M
Jun 2, 26

Christine Ring

Chief Legal Officer · 10b5-1

$6.4K

3.4K sh · $1.86

Own +19%
Grant·A
May 21, 26

Anil Kapur

Director

$0

36.0K sh

Own +216%
Grant·A
May 20, 26

Roger D Dansey

Director

$0

34.2K sh

Own New
Grant·A
May 20, 26

Roger D Dansey

Director

$0

41.8K sh

Own New
Grant·A
May 15, 26

Edward C Saltzman

Director

$0

31.2K sh

Own New
Grant·A
May 15, 26

Paul M Silva

Director

$0

31.2K sh

Own New
Grant·A
May 15, 26

Judith A Reinsdorf

Director

$0

31.2K sh

Own New
Grant·A
May 15, 26

David L. Lacey

Director

$0

31.2K sh

Own New
Grant·A
May 15, 26

Anil Kapur

Director

$0

31.2K sh

Own New
Grant·A
May 15, 26

Julia P Gregory

Director

$0

31.2K sh

Own New
Grant·A
May 15, 26

Roger D Dansey

Director

$0

31.2K sh

Own New
Sell·S
May 5, 26

Hans Van Houte KEY

Chief Financial Officer · 10b5-1

$10.0K

582 sh · $17.18

Own -2%
Sell·S
May 5, 26

Hans Van Houte KEY

Chief Financial Officer · 10b5-1

$223.3K

13.5K sh · $16.58

Own -26%
Sell·S
May 4, 26

Christine Ring

Chief Legal Officer · 10b5-1

$138.2K

8.1K sh · $16.96

Own -31%
Sell·S
May 1, 26

Christine Ring

Chief Legal Officer · 10b5-1

$90.4K

5.4K sh · $16.76

Own -17%
Exercise·M
Apr 30, 26

Hans Van Houte KEY

Chief Financial Officer

$0

2.9K sh

Own +14%
Exercise·M
Apr 30, 26

Hans Van Houte KEY

Chief Financial Officer

$0

3.8K sh

Own +33%
Exercise·M
Apr 30, 26

Hans Van Houte KEY

Chief Financial Officer

$0

2.0K sh

Own New
Sell·S
Apr 30, 26

Hans Van Houte KEY

Chief Financial Officer

$39.7K

2.4K sh · $16.65

Own -4%
Exercise·M
Apr 30, 26

Hans Van Houte KEY

Chief Financial Officer

$0

2.9K sh

Own +6%
Exercise·M
Apr 30, 26

Hans Van Houte KEY

Chief Financial Officer

$0

3.8K sh

Own +8%
Exercise·M
Apr 30, 26

Hans Van Houte KEY

Chief Financial Officer

$0

2.0K sh

Own +4%
Exercise·M
Apr 30, 26

Christine Ring

Chief Legal Officer

$0

2.9K sh

Own +14%
Exercise·M
Apr 30, 26

Christine Ring

Chief Legal Officer

$0

3.8K sh

Own +33%
Exercise·M
Apr 30, 26

Christine Ring

Chief Legal Officer

$0

2.0K sh

Own New
Sell·S
Apr 30, 26

Christine Ring

Chief Legal Officer

$53.5K

3.2K sh · $16.65

Own -9%
Exercise·M
Apr 30, 26

Christine Ring

Chief Legal Officer

$0

2.9K sh

Own +9%
Exercise·M
Apr 30, 26

Christine Ring

Chief Legal Officer

$0

3.8K sh

Own +13%
Exercise·M
Apr 30, 26

Christine Ring

Chief Legal Officer

$0

2.0K sh

Own +8%
Exercise·M
Apr 30, 26

Gwenn Hansen

Chief Scientific Officer

$0

2.9K sh

Own +14%
Exercise·M
Apr 30, 26

Gwenn Hansen

Chief Scientific Officer

$0

3.8K sh

Own +33%
Exercise·M
Apr 30, 26

Gwenn Hansen

Chief Scientific Officer

$0

2.0K sh

Own New
Sell·S
Apr 30, 26

Gwenn Hansen

Chief Scientific Officer

$53.5K

3.2K sh · $16.65

Own -3%
Exercise·M
Apr 30, 26

Gwenn Hansen

Chief Scientific Officer

$0

2.9K sh

Own +2%
Exercise·M
Apr 30, 26

Gwenn Hansen

Chief Scientific Officer

$0

3.8K sh

Own +3%
Exercise·M
Apr 30, 26

Gwenn Hansen

Chief Scientific Officer

$0

2.0K sh

Own +2%
Sell·S
Apr 2, 26

Christine Ring

Chief Legal Officer · 10b5-1

$124.1K

8.1K sh · $15.24

Own -24%

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
Jun 2, 2026	Christine Ring 10b5-1	Chief Legal Officer	Exercise M	3.4K	+190%	—	$0
Jun 2, 2026	Christine Ring 10b5-1	Chief Legal Officer	Sell S	8.1K	-38%	$16.60	$135.3K
Jun 2, 2026	Christine Ring 10b5-1	Chief Legal Officer	Exercise M	3.4K	+19%	$1.86	$6.4K
May 21, 2026	Anil Kapur	Director	Grant A	36.0K	+216%	—	$0
May 20, 2026	Roger D Dansey	Director	Grant A	34.2K	New	—	$0
May 20, 2026	Roger D Dansey	Director	Grant A	41.8K	New	—	$0
May 15, 2026	Edward C Saltzman	Director	Grant A	31.2K	New	—	$0
May 15, 2026	Paul M Silva	Director	Grant A	31.2K	New	—	$0
May 15, 2026	Judith A Reinsdorf	Director	Grant A	31.2K	New	—	$0
May 15, 2026	David L. Lacey	Director	Grant A	31.2K	New	—	$0
May 15, 2026	Anil Kapur	Director	Grant A	31.2K	New	—	$0
May 15, 2026	Julia P Gregory	Director	Grant A	31.2K	New	—	$0
May 15, 2026	Roger D Dansey	Director	Grant A	31.2K	New	—	$0
May 5, 2026	Hans Van Houte KEY 10b5-1	Chief Financial Officer	Sell S	582	-2%	$17.18	$10.0K
May 5, 2026	Hans Van Houte KEY 10b5-1	Chief Financial Officer	Sell S	13.5K	-26%	$16.58	$223.3K
May 4, 2026	Christine Ring 10b5-1	Chief Legal Officer	Sell S	8.1K	-31%	$16.96	$138.2K
May 1, 2026	Christine Ring 10b5-1	Chief Legal Officer	Sell S	5.4K	-17%	$16.76	$90.4K
Apr 30, 2026	Hans Van Houte KEY	Chief Financial Officer	Exercise M	2.9K	+14%	—	$0
Apr 30, 2026	Hans Van Houte KEY	Chief Financial Officer	Exercise M	3.8K	+33%	—	$0
Apr 30, 2026	Hans Van Houte KEY	Chief Financial Officer	Exercise M	2.0K	New	—	$0
Apr 30, 2026	Hans Van Houte KEY	Chief Financial Officer	Sell S	2.4K	-4%	$16.65	$39.7K
Apr 30, 2026	Hans Van Houte KEY	Chief Financial Officer	Exercise M	2.9K	+6%	—	$0
Apr 30, 2026	Hans Van Houte KEY	Chief Financial Officer	Exercise M	3.8K	+8%	—	$0
Apr 30, 2026	Hans Van Houte KEY	Chief Financial Officer	Exercise M	2.0K	+4%	—	$0
Apr 30, 2026	Christine Ring	Chief Legal Officer	Exercise M	2.9K	+14%	—	$0
Apr 30, 2026	Christine Ring	Chief Legal Officer	Exercise M	3.8K	+33%	—	$0
Apr 30, 2026	Christine Ring	Chief Legal Officer	Exercise M	2.0K	New	—	$0
Apr 30, 2026	Christine Ring	Chief Legal Officer	Sell S	3.2K	-9%	$16.65	$53.5K
Apr 30, 2026	Christine Ring	Chief Legal Officer	Exercise M	2.9K	+9%	—	$0
Apr 30, 2026	Christine Ring	Chief Legal Officer	Exercise M	3.8K	+13%	—	$0
Apr 30, 2026	Christine Ring	Chief Legal Officer	Exercise M	2.0K	+8%	—	$0
Apr 30, 2026	Gwenn Hansen	Chief Scientific Officer	Exercise M	2.9K	+14%	—	$0
Apr 30, 2026	Gwenn Hansen	Chief Scientific Officer	Exercise M	3.8K	+33%	—	$0
Apr 30, 2026	Gwenn Hansen	Chief Scientific Officer	Exercise M	2.0K	New	—	$0
Apr 30, 2026	Gwenn Hansen	Chief Scientific Officer	Sell S	3.2K	-3%	$16.65	$53.5K
Apr 30, 2026	Gwenn Hansen	Chief Scientific Officer	Exercise M	2.9K	+2%	—	$0
Apr 30, 2026	Gwenn Hansen	Chief Scientific Officer	Exercise M	3.8K	+3%	—	$0
Apr 30, 2026	Gwenn Hansen	Chief Scientific Officer	Exercise M	2.0K	+2%	—	$0
Apr 2, 2026	Christine Ring 10b5-1	Chief Legal Officer	Sell S	8.1K	-24%	$15.24	$124.1K

About NRIX insider trading

This page tracks insider transactions for Nurix Therapeutics, Inc. (NRIX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.